Cell and Gene Therapy CDMO Market Reaches USD 3.71 Billion in 2025 as Clinical Pipelines and Manufacturing Demand Expand

Expanding clinical pipelines and outsourcing are boosting CDMO demand. Opportunities include scalable cell/vector production, non-viral platforms, automation and faster analytics.

Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Contract Development and Manufacturing Organization - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

Cell and Gene Therapy CDMO Market Reaches USD 3.71 Billion in 2025 as Clinical Pipelines and Manufacturing Demand Expand

The global cell and gene therapy contract development and manufacturing organization (CDMO) market is valued at USD 3.71 billion in 2025. Strong clinical development activity, rising demand for advanced therapies, and growing reliance on outsourced manufacturing are supporting sustained market expansion. Key areas of activity include cell therapy, gene therapy, preclinical and clinical development, commercial manufacturing, process development, analytical testing, quality control, and fill-finish services.

Expanding Cell and Gene Therapy Clinical Pipeline Drives CDMO Demand

More than 2,000 active cell and gene therapy programs are in development worldwide, placing considerable pressure on manufacturing capacity commissioned before 2024. Regulatory initiatives, including the creation of the U.S. Food and Drug Administration's Office of Therapeutic Products, are helping streamline reviews as the number of potential therapy approvals increases.

Each cell and gene therapy candidate requires specialized production processes, including viral-vector manufacturing, cell expansion, cryopreservation, analytical testing, and quality-control workflows. Many therapy developers, particularly small and emerging biotechnology companies, lack the facilities and technical expertise needed to manage these processes internally. This capability Gap is increasing demand for experienced cell and gene therapy CDMOs.

Commercial approvals such as Casgevy and Lyfgenia have further validated the advanced therapy market and generated demand for multi-batch clinical and commercial supply. North America and Europe account for approximately 80% of clinical trials, creating capacity constraints and supporting PREMIUM pricing for qualified manufacturing services.

Genetic Diseases and Cancer Expand the Addressable Market

An estimated 400 million people worldwide live with a genetic disorder, while global cancer incidence continues to increase by approximately 2% to 3% annually. Advances in precision medicine are enabling developers to pursue disease targets that were previously difficult to address, particularly through cell-based treatments and vector-enabled gene therapies.

Commercial CAR-T therapies, which can carry list prices of USD 400,000 to USD 500,000, demonstrate payer acceptance of high-value, one-time interventions when clinical benefits are substantial. Aging populations in high-income countries are also expanding the number of eligible patients. As cell and gene therapies move into larger indications, CDMOs capable of producing higher batch volumes are expected to gain significant market opportunities.

Additional growth drivers include increased venture capital and pharmaceutical funding, along with a strong outsourcing preference among smaller therapy developers. However, manual-intensive production, complex regulatory requirements, and limited specialized talent remain barriers to faster market expansion.

Analytical Testing Remains a Key Manufacturing Constraint

Large-scale adeno-associated virus production continues to face analytical bottlenecks. Complete lot-release testing can require up to four weeks because of demanding capsid-ratio assays, genome-integrity testing, and other quality requirements. Slow turnaround times restrict manufacturing throughput and increase inventory and operating costs.

Automation, inline process monitoring, and machine-learning-supported release systems could improve efficiency, but regulatory validation requirements may delay widespread adoption. CDMOs that invest in advanced analytical platforms and faster quality-control workflows are likely to achieve meaningful differentiation in the global cell and gene therapy manufacturing market.

Cell Therapy Maintains Market Leadership

Cell therapy represented 69.98% of the cell and gene therapy CDMO market in 2025, supported by commercial CAR-T products and an expanding pipeline of allogeneic therapies. Stem-cell platforms retain a major position because of established expansion, cryopreservation, and quality-control processes. Engineered approaches, including CAR-NK and gamma delta T-cell therapies, are also advancing as gene-editing technologies help shorten development timelines.

Gene therapy is projected to record a compound annual growth rate of 16.85% through 2031. Viral vectors, particularly adeno-associated viruses, continue to command strong pricing due to their safety profiles and ability to Target specific tissues. Non-viral technologies, including lipid nanoparticles and minicircle DNA, are attracting investment because of their potential to reduce immunogenicity and overcome some viral-vector scaling limitations.

Manufacturing capacity is also evolving. Batch sizes for allogeneic cell therapies are forecast to increase fivefold, supporting demand for 2,000-liter closed bioreactors and automated sterile systems. Gene therapy production is moving from 200-liter batches toward 1,000- to 2,000-liter single-use fermenters, helping reduce the cost per dose. CDMOs with both cell and gene therapy capabilities can improve facility utilization by sharing selected upstream operations across multiple programs.

Regional Cell and Gene Therapy CDMO Market Outlook

North America generated 43.75% of global market revenue in 2025. The region benefits from established regulatory pathways, a dense biotechnology ecosystem, substantial early-stage investment, and a high concentration of clinical trials. However, elevated operating costs and shortages of specialized workers are contributing to longer delivery timelines and higher process-development fees.

Asia-Pacific is forecast to post the fastest regional growth, with a 16.12% compound annual growth rate through 2031. Government-backed life sciences infrastructure, expanding manufacturing capacity, competitive labor costs, and accelerated regulatory pathways are strengthening the region's position. China, Japan, South Korea, and Singapore are emerging as important centers for advanced therapy development and production.

Europe remains a mature cell and gene therapy manufacturing market supported by centralized authorization procedures, experienced facilities, and strong technical talent. Growth is moderated by differing national inspection requirements and higher energy costs. Nevertheless, new investment in countries such as Ireland and Portugal, combined with Europe's role in global batch release and cross-border clinical supply, continues to support long-term market development.

Key Topics Covered:

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise In CGT Clinical Pipeline
4.2.2 Rising Prevalence Of Genetic Diseases & Cancer
4.2.3 VC & Big-Pharma Funding Surge
4.2.4 Outsourcing Preference Of Small CGT Developers
4.2.5 Allogeneic 'Off-The-Shelf' Platforms Needing Large-Batch CDMO Capacity
4.2.6 Global CMC Dossier Harmonisation (FDA-EMA-PMDA) Shortening Multi-Region Launches
4.3 Market Restraints
4.3.1 Limited High-Throughput Analytics For Large-Scale AAV Production
4.3.2 Complex, Manual-Intensive Manufacturing & Regulatory Hurdles
4.3.3 Shortage Of GMP-Grade Plasmid & Viral Raw Materials
4.3.4 Post-COVID CDMO Over-Capacity Driving Margin Squeeze
4.4 Supply Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value)
5.1 By Product
5.1.1 Cell Therapy
5.1.1.1 Stem-cell-based
5.1.1.2 Non-stem-cell-based
5.1.1.3 Other cell therapies
5.1.2 Gene Therapy
5.1.2.1 Viral Vectors
5.1.2.2 Non-viral Vectors
5.2 By Stage
5.2.1 Pre-clinical
5.2.2 Clinical
5.2.3 Commercial
5.3 By Service Type
5.3.1 Process Development
5.3.2 GMP Manufacturing
5.3.3 Analytical Testing / QC
5.3.4 Fill-Finish & Packaging
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 South Korea
5.4.3.5 Australia
5.4.3.6 Rest of Asia Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
6.3.1 Lonza
6.3.2 Catalent Inc
6.3.3 Thermo Fisher Scientific (Patheon)
6.3.4 WuXi Advanced Therapies
6.3.5 Samsung Biologics
6.3.6 AGC Biologics
6.3.7 Charles River Labs (Cognate)
6.3.8 Recipharm AB
6.3.9 FUJIFILM Diosynth Biotechnologies
6.3.10 Minaris Regenerative Medicine
6.3.11 PCI Pharma Services
6.3.12 Almac Group
6.3.13 Pfizer CentreOne
6.3.14 KBI Biopharma
6.3.15 BioCentriq
6.3.16 ElevateBio
6.3.17 Yposkesi
6.3.18 Genezen
6.3.19 3P Biopharmaceuticals
6.3.20 Oxford Biomedica

7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/kbxibt

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900